|
1
|
Welzel TM, McGlynn KA, Hsing AW, O'Brien
TR and Pfeiffer RM: Impact of classification of hilar
cholangiocarcinomas (Klatskin tumors) on the incidence of intra-
and extrahepatic cholangiocarcinoma in the United States. J Natl
Cancer Inst. 98:873–875. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Khan SA, Davidson BR, Goldin RD, Heaton N,
Karani J, Pereira SP, Rosenberg WM, Tait P, Taylor-Robinson SD,
Thillainayagam AV, et al: British Society of Gastroenterology:
Guidelines for the diagnosis and treatment of cholangiocarcinoma:
An update. Gut. 61:1657–1669. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Everhart JE and Ruhl CE: Burden of
digestive diseases in the United States Part III: Liver, biliary
tract, and pancreas. Gastroenterology. 136:1134–1144. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tyson GL and El-Serag HB: Risk factors for
cholangiocarcinoma. Hepatology. 54:173–184. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Libby G, Donnelly LA, Donnan PT, Alessi
DR, Morris AD and Evans JM: New users of metformin are at low risk
of incident cancer: A cohort study among people with type 2
diabetes. Diabetes Care. 32:1620–1625. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Landman GW, Kleefstra N, van Hateren KJ,
Groenier KH, Gans RO and Bilo HJ: Metformin associated with lower
cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care.
33:322–326. 2010. View Article : Google Scholar :
|
|
8
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar
|
|
9
|
Anisimov VN, Egormin PA, Piskunova TS,
Popovich IG, Tyndyk ML, Yurova MN, Zabezhinski MA, Anikin IV,
Karkach AS and Romanyukha AA: Metformin extends life span of
HER-2/neu transgenic mice and in combination with melatonin
inhibits growth of transplantable tumors in vivo. Cell Cycle.
9:188–197. 2010. View Article : Google Scholar
|
|
10
|
Zhou XZ, Xue YM, Zhu B and Sha JP: Effects
of metformin on proliferation of human colon carcinoma cell line
SW-480. Nan Fang Yi Ke Da Xue Xue Bao. 30:1935–1938. 2010.In
Chinese.
|
|
11
|
Kato K, Gong J, Iwama H, Kitanaka A, Tani
J, Miyoshi H, Nomura K, Mimura S, Kobayashi M, Aritomo Y, et al:
The anti-diabetic drug metformin inhibits gastric cancer cell
proliferation in vitro and in vivo. Mol Cancer Ther. 11:549–560.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kobayashi M, Kato K, Iwama H, Fujihara S,
Nishiyama N, Mimura S, Toyota Y, Nomura T, Nomura K, Tani J, et al:
Anti-tumor effect of metformin in esophageal cancer: In vitro
study. Int J Oncol. 42:517–524. 2013.
|
|
13
|
Fujihara S, Kato K, Morishita A, Iwama H,
Nishioka T, Chiyo T, Nishiyama N, Miyoshi H, Kobayashi M, Kobara H,
et al: Antidiabetic drug metformin inhibits esophageal
adenocarcinoma cell proliferation in vitro and in vivo. Int J
Oncol. 46:2172–2180. 2015.PubMed/NCBI
|
|
14
|
Miyoshi H, Kato K, Iwama H, Maeda E,
Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al:
Effect of the anti-diabetic drug metformin in hepatocellular
carcinoma in vitro and in vivo. Int J Oncol. 45:322–332.
2014.PubMed/NCBI
|
|
15
|
Masaki T, Tokuda M, Yoshida S, Nakai S,
Morishita A, Uchida N, Funaki T, Kita Y, Funakoshi F, Nonomura T,
et al: Comparison study of the expressions of myristoylated
alanine-rich C kinase substrate in hepatocellular carcinoma, liver
cirrhosis, chronic hepatitis, and normal liver. Int J Oncol.
26:661–671. 2005.PubMed/NCBI
|
|
16
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Towbin H, Staehelin T and Gordon J:
Electrophoretic transfer of proteins from polyacrylamide gels to
nitrocellulose sheets: Procedure and some applications. Proc Natl
Acad Sci USA. 76:4350–4354. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
D'Incalci M, Colombo T, Ubezio P,
Nicoletti I, Giavazzi R, Erba E, Ferrarese L, Meco D, Riccardi R,
Sessa C, et al: The combination of yondelis and cisplatin is
synergistic against human tumor xenografts. Eur J Cancer.
39:1920–1926. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
DeOliveira ML, Cunningham SC, Cameron JL,
Kamangar F, Winter JM, Lillemoe KD, Choti MA, Yeo CJ and Schulick
RD: Cholangiocarcinoma: Thirty-one-year experience with 564
patients at a single institution. Ann Surg. 245:755–762. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Patel T: Increasing incidence and
mortality of primary intrahepatic cholangiocarcinoma in the United
States. Hepatology. 33:1353–1357. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hezel AF and Zhu AX: Systemic therapy for
biliary tract cancers. Oncologist. 13:415–423. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bailey CJ and Turner RC: Metformin. N Engl
J Med. 334:574–579. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Stang M, Wysowski DK and Butler-Jones D:
Incidence of lactic acidosis in metformin users. Diabetes Care.
22:925–927. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vazquez-Martin A, Oliveras-Ferraros C and
Menendez JA: The antidiabetic drug metformin suppresses HER2
(erbB-2) oncoprotein overexpression via inhibition of the mTOR
effector p70S6K1 in human breast carcinoma cells. Cell Cycle.
8:88–96. 2009. View Article : Google Scholar
|
|
28
|
Vázquez-Martín A, Oliveras-Ferraros C, del
Barco S, Martín-Castillo B and Menéndez JA: mTOR inhibitors and the
anti-diabetic biguanide metformin: New insights into the molecular
management of breast cancer resistance to the HER2 tyrosine kinase
inhibitor lapatinib (Tykerb). Clin Transl Oncol. 11:455–459. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chaiteerakij R, Yang JD, Harmsen WS,
Slettedahl SW, Mettler TA, Fredericksen ZS, Kim WR, Gores GJ,
Roberts RO, Olson JE, et al: Risk factors for intrahepatic
cholangiocarcinoma: Association between metformin use and reduced
cancer risk. Hepatology. 57:648–655. 2013. View Article : Google Scholar :
|
|
30
|
Razumilava N and Gores GJ:
Cholangiocarcinoma. Lancet. 383:2168–2179. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ling S, Feng T, Ke Q, Fan N, Li L, Li Z,
Dong C, Wang C, Xu F, Li Y, et al: Metformin inhibits proliferation
and enhances chemosensitivity of intrahepatic cholangiocarcinoma
cell lines. Oncol Rep. 31:2611–2618. 2014.PubMed/NCBI
|
|
33
|
Masaki T, Shiratori Y, Rengifo W, Igarashi
K, Yamagata M, Kurokohchi K, Uchida N, Miyauchi Y, Yoshiji H,
Watanabe S, et al: Cyclins and cyclin-dependent kinases:
Comparative study of hepatocellular carcinoma versus cirrhosis.
Hepatology. 37:534–543. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Imamura K, Ogura T, Kishimoto A, Kaminishi
M and Esumi H: Cell cycle regulation via p53 phosphorylation by a
5′-AMP activated protein kinase activator,
5-amino-imidazole-4-carboxamide-1-beta-D-ribofuranoside, in a human
hepatocellular carcinoma cell line. Biochem Biophys Res Commun.
287:562–567. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Jones RG, Plas DR, Kubek S, Buzzai M, Mu
J, Xu Y, Birnbaum MJ and Thompson CB: AMP-activated protein kinase
induces a p53-dependent metabolic checkpoint. Mol Cell. 18:283–293.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang J, Shao SH, Xu ZX, Hennessy B, Ding
Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, et al:
The energy sensing LKB1-AMPK pathway regulates p27(kip1)
phosphorylation mediating the decision to enter autophagy or
apoptosis. Nat Cell Biol. 9:218–224. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zhuang Y and Miskimins WK: Cell cycle
arrest in metformin treated breast cancer cells involves activation
of AMPK, down-regulation of cyclin D1, and requires
p27Kip1 or p21Cip1. J Mol Signal. 3:182008.
View Article : Google Scholar
|
|
38
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Han S, Kim HY, Park K, Lee MS, Kim HJ and
Kim YD: Expression of p27Kip1 and cyclin D1 proteins is inversely
correlated and is associated with poor clinical outcome in human
gastric cancer. J Surg Oncol. 71:147–154. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Aoyagi K, Koufuji K, Yano S, Murakami N,
Terasaki Y, Yamasaki Y, Takeda J, Tanaka M and Shirouzu K:
Immunohistochemical study on the expression of cyclin D1 and E in
gastric cancer. Kurume Med J. 47:199–203. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Vazquez-Martin A, Oliveras-Ferraros C,
Cufí S, Martin-Castillo B and Menendez JA: Metformin activates an
ataxia telangiectasia mutated (ATM)/Chk2-regulated DNA damage-like
response. Cell Cycle. 10:1499–1501. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Morishita A and Masaki T: miRNA in
hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar
|
|
43
|
Barroso-del Jesus A, Lucena-Aguilar G and
Menendez P: The miR-302-367 cluster as a potential stemness
regulator in ESCs. Cell Cycle. 8:394–398. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Card DA, Hebbar PB, Li L, Trotter KW,
Komatsu Y, Mishina Y and Archer TK: Oct4/Sox2-regulated miR-302
targets cyclin D1 in human embryonic stem cells. Mol Cell Biol.
28:6426–6438. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yan GJ, Yu F, Wang B, Zhou HJ, Ge QY, Su
J, Hu YL, Sun HX and Ding LJ: MicroRNA miR-302 inhibits the
tumorigenicity of endometrial cancer cells by suppression of cyclin
D1 and CDK1. Cancer Lett. 345:39–47. 2014. View Article : Google Scholar
|
|
46
|
Jiang X, Ma N, Wang D, Li F, He R, Li D,
Zhao R, Zhou Q, Wang Y, Zhang F, et al: Metformin inhibits tumor
growth by regulating multiple miRNAs in human cholangiocarcinoma.
Oncotarget. 6:3178–3194. 2015. View Article : Google Scholar : PubMed/NCBI
|
